What does remeasurement of share-based liability mean?

The periodic adjustment to the carrying value of share-based liabilities to reflect changes in the fair value of the underlying equity instruments. This metric captures the volatility of compensation-related liabilities that must be marked-to-market.

BioCryst Pharmaceuticals BCRX Remeasurement of share-based liability

Remeasurement of share-based liability at other companies

Crane NXT, Inc.CXT

$1M+42.9%

ZymeworksZYME

-$60K+66.1%

Sarepta Therapeutics, Inc.SRPT

$3.07M—

Churchill DownsCHDN

$5.23M—

Equitable HoldingsEQH

-$9M-550%

Equitable HoldingsEQH

-$9M-550%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:AdjustmentsToAdditionalPaidInCapitalRemeasurementOfShareBasedLiability.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's remeasurement of share-based liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's remeasurement of share-based liability?: BioCryst Pharmaceuticals (BCRX) reported remeasurement of share-based liability of -$637K in Q1 2026.
How has BioCryst Pharmaceuticals's remeasurement of share-based liability changed year-over-year?: BioCryst Pharmaceuticals's remeasurement of share-based liability decreased by 224.3% year-over-year, from $512.5K to -$637K.
What does remeasurement of share-based liability mean?: The periodic adjustment to the carrying value of share-based liabilities to reflect changes in the fair value of the underlying equity instruments. This metric captures the volatility of compensation-related liabilities that must be marked-to-market.